Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases.
GHRH
MRI
T2-hypointense
acromegaly
ectopic
neuroendocrine tumor
pituitary
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
14 07 2022
14 07 2022
Historique:
received:
09
11
2021
pubmed:
6
5
2022
medline:
19
7
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
Ectopic acromegaly is a consequence of rare neuroendocrine tumors (NETs) that secrete GHRH. This abnormal GHRH secretion drives GH and IGF-1 excess, with a clinical presentation similar to classical pituitary acromegaly. Identifying the underlying cause for the GH hypersecretion in the setting of ectopic GHRH excess is, however, essential for proper management both of acromegaly and the NET. Owing to the rarity of NETs, the imaging characteristics of the pituitary in ectopic acromegaly have not been analyzed in depth in a large series. Characterize pituitary magnetic resonance imaging (MRI) features at baseline and after NET treatment in patients with ectopic acromegaly. Multicenter, international, retrospective. Tertiary referral pituitary centers. Thirty ectopic acromegaly patients having GHRH hypersecretion. None. MRI characteristics of pituitary gland, particularly T2-weighted signal. In 30 patients with ectopic GHRH-induced acromegaly, we found that most patients had hyperplastic pituitaries. Hyperplasia was usually moderate but was occasionally subtle, with only small volume increases compared with normal ranges for age and sex. T2-weighted signal was hypointense in most patients, especially in those with hyperplastic pituitaries. After treatment of the NET, pituitary size diminished and T2-weighted signal tended to normalize. This comprehensive study of pituitary MRI characteristics in ectopic acromegaly underlines the utility of performing T2-weighted sequences in the MRI evaluation of patients with acromegaly as an additional tool that can help to establish the correct diagnosis.
Identifiants
pubmed: 35512251
pii: 6580500
doi: 10.1210/clinem/dgac274
doi:
Substances chimiques
Growth Hormone-Releasing Hormone
9034-39-3
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3313-e3320Subventions
Organisme : Albert Beckers by the Fonds d'Investissment pour la Recherche
Organisme : Centre Hospitalier Universitaire de Liege
ID : 2018-2020
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.